

## A Novel Prokineticin Receptor 1 (PKR1) Signaling Inhibitor

<b>Drug Name</b>	GPCR-targeted Project 005
<b>Description</b>	Prokineticins (PK1 and PK2) are peptide hormones that exert their biological activities, such as modulating cell survival, cell motility, and cell excitability, through two common G-protein-coupled receptors: prokineticin receptor (PKR) 1 and 2. A monoclonal antibody is being developing as an inhibitor of prokineticin receptor 1 (PKR1) for the treatment of inflammation. Early research is under way.
<b>Target</b>	Prokineticin receptor 1 (PKR1)
<b>Drug Modality</b>	Monoclonal antibody
<b>Indication</b>	Inflammation
<b>Product Category</b>	Biologic
<b>Mechanism of Action</b>	PKR1 inhibitors
<b>Status</b>	Preclinical
<b>Patent</b>	Granted

### More Detail Available Upon Request

We look forward to hearing from you.